"Study: 12 Weeks Therapy Combination Cures Virtually All HCV Patients" - Mark L. Fuerst
Eight weeks of therapy with a combination of sofosbuvir, velpatasvir and voxilaprevir does not appear to be as effective as 12 weeks of sofosbuvir plus velpatasvir in patients with chronic hepatitis C virus (HCV) infection, according to the results of two phase 3 randomized clinical trials. Researchers led by Ira M. Jacobson, MD, chair of the Department of Medicine at Mount Sinai Beth Israel assessed the efficacy of eight weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir in comparison to standard 12 weeks of sofusbuvir-velpatasvir.
- Ira M. Jacobson, MD, Chair, Department of Medicine, Mount Sinai Beth Israel
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
